BUZZ-Tekmira Pharmaceuticals Corp: Brokerage downgrade

Mon Oct 6, 2014 7:59am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Drugmaker's U.S.-listed shares down 5 pct at $28 premarket

** Analysts at Leerink Partners downgrades to "market perform" from "outperform," citing valuation and limited near-term visibility on stock-moving catalysts

** Analysts said significant profits from the company's Ebola treatment, TKM-Ebola, is now "baked" into the stock

** Tekmira is one of the several companies developing treatments or vaccines for Ebola

** The stock has risen about 40 pct in the last one week on hopes that the Canadian company could win a U.S. contract for its Ebola treatment after the first case of the deadly infection was diagnosed in the United States

** Out of five analysts covering the stock, four have a "buy" or a higher rating and one has a "hold", according to Thomson Reuters data

** Up to Friday's close, the stock had risen 129 pct since May 27, a day after Sierra Leone first confirmed Ebola outbreak